Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Pancreatic Neoplasms 2Neoplasms 2Neoplasm Metastasis 2Gastrinoma 2Adenoma, Islet Cell 2Zollinger-Ellison Syndrome 1Somatostatinoma 1Rectal Neoplasms 1Rare Diseases 1Oligodendroglioma 1Insulinoma 1Glucagonoma 1Glioma 1Glioblastoma 1Genetic Diseases, Inborn 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Islet Cell 1Brain Neoplasms 1Astrocytoma 1Adrenocortical Carcinoma 1

Interventions

Octreotide 4Everolimus 4Capecitabine 4Temozolomide 3Leucovorin 3vatalanib 2Trastuzumab 2Oxaliplatin 2Fluorouracil 2Bortezomib 2Bevacizumab 2veliparib 1tipifarnib 1romidepsin 1regorafenib 1pentetreotide 1pazopanib 1motesanib diphosphate 1cixutumumab 1batifiban 1Thalidomide 1Streptozocin 1Sorafenib 1Salts 1Panobinostat 1Melphalan 1Irinotecan 1Interleukin-12 Subunit p35 1Interleukin-12 1High-Energy Shock Waves 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Glucagonoma × Streptozocin × Clear all
NCT00602082 2013-08-07

Capecitabine and Streptozocin With or Without Cisplatin in Treating Patients With Unresectable or Metastatic Neuroendocrine Tumors

National Cancer Institute (NCI)

Phase 2 Completed
84 enrolled
Endocrine

Glucagonoma, Insulinoma, Adenoma, Islet Cell, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡